Mission Possible

Boldly recognizing that the opportunity to conquer cancer is within reach, Dana-Farber has launched a $1 billion capital campaign - the largest and most ambitious fundraising campaign in its history. Be a part of it.

Featured Research

2007 Susan Swerling Lectures - View the video >>

 

 

Read More

Radiation Oncology
in the News

February 27, 2007 - Androgen deprivation therapy >>

Androgen deprivation therapy - one of the most common treatments for prostate cancer - may increase the risk of death from heart disease in patients over age 65, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital and other institutions.

Read More

Subscribe

newsletter

Sign up to receive the Dana-Farber Cancer Institute Monthly E-mail Newsletter.
Subscribe

Message from the Department Chair

Jay R. Harris, MD

Jay R. Harris, MD, Chair

The Department of Radiation Oncology at Dana-Farber is committed to combining advances in clinical and laboratory research with developments in radiation physics to promote not only a better understanding of the biology of cancer and normal tissues but also improved treatment of cancer. The department is part of the combined effort in Radiation Oncology between DFCI, Brigham and Women's Hospital, and Children's Hospital.

Message from the Research ChIEF

Alan D. D'Andrea, MD

Alan D. D'Andrea, MD

Our laboratory examines the molecular signaling pathways which regulate the DNA damage response in mammalian cells. Disruption of these pathways, by germline or somatic mutation, leads to genomic instability, cellular sensitivity to ionizing radiation, and defective cell cycle checkpoints and DNA repair. These pathways are often disrupted in cancer cells, accounting for the chromosome instability and increase mutation frequency in human tumors.

Profiles


  • Harvard Affiliate
  • NCI CCC
  • Dana-Farber
  • Magnet Status